Hearing Loss
Conditions
Keywords
Cochlear Implant aftercare, Remote clinical management
Brief summary
The aim of the study is to assess the real-world effectiveness of managing participants within the first year post-activation (between 3 and 12 months) using Cochlear's Remote Care (Remote Check and Remote Assist), as compared with standard in-clinic management. The study captures also the time and costs associated with both models of care to quantify the potential costs savings and efficiency gains possible with delivering Cochlear Implant (CI) aftercare remotely.
Interventions
PROCEDURECochlear™ Remote care
Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review. Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit.
PROCEDUREStandard of care
Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
DEVICECompatible Implant Series and Compatible Sound Processors
Individuals who are implanted with a compatible cochlear implant series and compatible sound processor are eligible to participate.
Sponsors
Cochlear
QbD Clinical
Avania
TFS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older (no upper age limit) * Post-lingually deafened or pre-lingually deafened with measurable word scores in quiet using a cochlear implant * Unilaterally implanted with a compatible Cochlear™ implant * Currently using a compatible Cochlear™ Sound Processor * 3 months, +/- 2 weeks, experience with a cochlear implant (post-activation) at the time of baseline measurements * Direct access to a compatible Smart Phone * Fluent in the languages used for the study, as determined by the investigator * Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm * Willing and able to provide written informed consent
Exclusion criteria
* Patient has a MAP incompatible with Master Volume, Bass and Treble (MVBT) programming: * Non-monopolar MAPs (bipolar, common ground, variable mode) * Dynamic range of \<10 Comfortable Level (CL) * Hybrid mode enabled * Pulse widths \>100 µs * 10 or more electrodes turned off * Patient has on-going fluctuations in MAP Threshold levels (Ts) and Comfort levels (Cs) and/or impedances * Patient requires frequent individual channel measurements and/or measurements without the use of live-stimulation * Score below 3 on the screening subset of questions from the Mobile Device Proficiency Questionnaire (MDPQ) * Abnormal cochlea anatomy and/or facial nerve stimulation that requires complex or more frequent programming, as determined by the Investigator * Additional disabilities that would prevent participation in evaluations, including significant visual impairment and/or dexterity issues * Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator * Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling * Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation * Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in patient reported hearing ability in daily life measured with the SSQ12 (Speech, Spatial and Qualities of Hearing Scale) questionnaire between month 3 (baseline) and month 12 post-activation | 3 months post-activation (baseline) and 12 months post-activation | Measuring change of speech, spatial and hearing experiences (12 items). Each item is scored on a scale of 0 to 10 where 0 corresponds to "complete inability or complete absence of a quality" and 10 to "complete ability or complete presence of an ability". The score of a participant is determined as the mean of the 12 items. Higher scores indicate less hearing disability |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in speech recognition score for an open-set word recognition measure in quiet between 3 months post-activation (baseline) and 12 months post-activation | 3 months post-activation (baseline) and 12 months post-activation | The test is done using phonetically balanced words and scores are recorded as % correct words. Higher scores indicate a better outcome. |
| Mean change in speech recognition score for sentences in adaptive noise between 3 months post-activation (baseline) and 12 months post-activation | 3 months post-activation (baseline) and 12 months post-activation | The test is done using validated lists of phonetically balanced sentences. The noise is kept constant at 65 decibel (dB) Sound Pressure Level (SPL), and the speech is adapted stepwise to establish the speech-to-noise ratio (SNR) providing a 50% level of understanding. Lower scores indicate a better outcome. |
| Descriptive summaries of clinic time and resource utilisation incurred between 3 months and 12 months post-activation assessed via a custom questionnaire. | 3 months post-activation (baseline) and 12 months post-activation | — |
| Descriptive summaries of time and costs incurred by participants between 3 months and 12 months post-activation via a custom questionnaire | 3 months post-activation (baseline) and 12 months post-activation | — |
| Participant satisfaction measured with the Client Satisfaction Questionnaire (CSQ)-8 at 12 months post-activation | 12 months post-activation | Measuring satisfaction of participants with the healthcare service (8 questions). Each item is scored using a 4-point Likert scale with 1 always indicating a negative response and 4 a positive response. A total higher score indicates higher satisfaction |
| Participant empowerment measured with the Patient Activation Measure (PAM), at 12 months post-activation | 12 months post-activation | Evaluating the knowledge, skills, beliefs, and behaviours that participants have for self-management of their long-term health condition (13 items). Each item is scored on a 4-point likert scale from 1 (strongly disagree) to 4 (strongly agree). The overall score is calculated and normalized to a 100-point scale. Higher scores indicate greater levels of activation. |
Countries
Australia, Belgium, Italy, Netherlands, United Kingdom
Contacts
STUDY_DIRECTORKatie Keyrouse
Cochlear
Outcome results
None listed